secwatch.observer — SEC 8-K summary
======================================

Issuer:     INOVIO PHARMACEUTICALS, INC. (INO)
CIK:        0001055726
Form:       8-K
Filed at:   2026-03-12T23:59:59+00:00
Accession:  0001055726-26-000009
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inovio reports FY 2025 net loss $84.9M; INO-3107 BLA accepted with PDUFA Oct 30, 2026
--------------------------------------------------------------------------------

- Q4 2025 net income $3.8M ($0.06 basic EPS) mainly from $21.2M non-cash warrant gain; FY net loss $84.9M ($1.81/share).
- Cash, equivalents & short-term investments $58.5M as of Dec 31, 2025; estimated runway into Q4 2026 with Q1 2026 burn ~$22M.
- FDA accepted BLA for INO-3107 under accelerated approval program; PDUFA date Oct 30, 2026; FDA questioned accelerated eligibility.
- Published INO-3107 Phase 1/2 and long-term data in Nature Communications and The Laryngoscope showing reduced surgeries.
- Entered clinical trial collaboration with Akeso to evaluate INO-5412 + cadonilimab for glioblastoma in Dana-Farber INSIGhT trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1055726/000105572626000009/0001055726-26-000009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1055726/000105572626000009/ino-20260312.htm
  HTML page:      https://secwatch.observer/filing/0001055726-26-000009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer